Tendinitis: Drugs That Cause or Treat It

What Is Tendinitis and Why Do Drugs Matter?

Tendinitis is inflammation or irritation of a tendon, the thick fibrous cord connecting muscle to bone. It causes pain, swelling, and restricted movement at the affected joint. While overuse and repetitive strain account for most cases, medications are an underrecognized contributor that clinicians and patients should not overlook.

The relationship between drugs and tendons runs in two directions. Some medications directly damage tendon collagen or impair repair mechanisms, raising the risk of tendinopathy and rupture. Others reduce inflammation and pain, making them therapeutic tools for managing the condition. A 2019 review in the British Journal of Sports Medicine identified at least six drug classes associated with tendon disorders, yet many prescribers and patients remain unaware of these connections [1]. Understanding both categories matters for anyone dealing with persistent tendon pain or taking long-term medications. The Achilles, rotator cuff, and patellar tendons are most commonly affected by drug-induced tendinopathy, though any tendon can be involved.

Fluoroquinolones: The Biggest Drug-Related Tendon Risk

Fluoroquinolone antibiotics carry the strongest and most well-documented link to tendinitis. The FDA added a black-box warning to all fluoroquinolones in 2008 after accumulating evidence of tendon damage and rupture [2]. Ciprofloxacin, levofloxacin, and moxifloxacin are the most commonly implicated agents.

The mechanism involves direct toxicity to tenocytes (tendon cells). Fluoroquinolones inhibit DNA gyrase and topoisomerase IV, which disrupts collagen synthesis and promotes matrix metalloproteinase activity that degrades the tendon structure. A meta-analysis published in the European Journal of Clinical Pharmacology found that fluoroquinolone use increased tendon rupture risk by a factor of 1.98 (95% CI 1.74-2.26) compared with non-use [3].

Risk factors compound the danger. Patients over age 60 face the highest risk. Concurrent corticosteroid use multiplies the hazard further. A population-based study of 6,691 Achilles tendon ruptures in the Netherlands found the adjusted odds ratio rose to 4.1 among patients over 60 taking both fluoroquinolones and oral corticosteroids [4]. Kidney transplant recipients and those with renal impairment are also at elevated risk because reduced drug clearance extends tendon exposure.

Tendinitis symptoms typically appear within the first 30 days of fluoroquinolone use, though cases have been reported up to 6 months after discontinuation. The Achilles tendon is involved in 89% to 100% of fluoroquinolone-associated cases. Bilateral involvement occurs in roughly one-third of patients.

Clinical recommendation from the FDA: "Discontinue fluoroquinolone treatment immediately if a patient reports tendon pain, swelling, or inflammation. Avoid fluoroquinolones in patients who have a history of tendon disorders or who are taking corticosteroids" [2].

Statins and Other Drugs Linked to Tendinopathy

Fluoroquinolones dominate the conversation, but other medication classes also contribute to tendon problems. Statin-associated tendinopathy has gained increasing recognition over the past decade.

Statins. HMG-CoA reductase inhibitors (atorvastatin, rosuvastatin, simvastatin) can cause tendinopathy through disruption of cholesterol metabolism in tenocytes and altered mitochondrial function. A French pharmacovigilance study analyzing 4,597 statin-related adverse events identified tendinous disorders in 2,002 reports, with the Achilles tendon most frequently affected [5]. Symptoms typically resolve within weeks of drug discontinuation, though some cases require months. Onset occurs most often within the first year of statin therapy.

Aromatase inhibitors. Anastrozole, letrozole, and exemestane, used in hormone-receptor-positive breast cancer, produce musculoskeletal symptoms in 35% to 50% of patients. A study in The Lancet Oncology reported that aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) caused treatment discontinuation in 20% of patients [6]. Estrogen depletion appears to reduce tendon elasticity and increase stiffness, particularly affecting the hands, wrists, and shoulders.

Isotretinoin. This acne medication has been associated with skeletal and tendon abnormalities in case reports, particularly involving the Achilles tendon [7]. Isotretinoin affects retinoid receptors in connective tissue, potentially altering collagen turnover. The risk appears dose-dependent.

Other implicated agents include:

• GnRH agonists (leuprolide, goserelin) through estrogen/testosterone suppression
• Anabolic steroids, which increase tendon stiffness while boosting muscle strength, creating a force mismatch
• Chronic systemic corticosteroids, which impair collagen synthesis over time

NSAIDs: The First-Line Treatment for Acute Tendinitis

Non-steroidal anti-inflammatory drugs remain the primary pharmacologic treatment for tendinitis pain and inflammation. Both oral and topical formulations are effective, though their role differs based on the phase and severity of tendon disease.

Oral NSAIDs provide systemic anti-inflammatory and analgesic effects through cyclooxygenase (COX) inhibition. Ibuprofen (400-800 mg three times daily) and naproxen (250-500 mg twice daily) are the most commonly prescribed agents. A Cochrane review of topical and oral NSAIDs for musculoskeletal conditions confirmed that both formulations reduce pain effectively in the first 7 to 14 days of acute tendinitis [8]. Short courses of 7 to 10 days are recommended to minimize gastrointestinal, cardiovascular, and renal risks.

Topical NSAIDs offer a targeted alternative with a better safety profile. Topical diclofenac gel (1%) applied four times daily to the affected area achieves therapeutic concentrations in superficial tendons while producing 70% to 80% lower systemic drug levels than oral formulations [9]. For tendons close to the skin surface (Achilles, patellar, lateral epicondyle), topical application can match oral NSAID efficacy. The American Academy of Orthopaedic Surgeons (AAOS) supports topical NSAIDs as a first-line option for lateral epicondylitis.

One important caveat: NSAIDs address symptoms but do not promote tendon healing. Preclinical data suggest that COX-2 inhibition may actually impair the early inflammatory phase of tendon repair. For chronic tendinopathy lasting longer than 6 weeks, the inflammatory component is often minimal, making NSAIDs less useful. In these cases, physical therapy and eccentric loading exercises become the primary intervention, with NSAIDs reserved for acute flares.

Dr. Karim Khan, professor of sports medicine at the University of British Columbia, has noted: "Calling chronic tendon pain 'tendinitis' implies ongoing inflammation, but biopsies consistently show degenerative changes, not inflammatory cells. The treatment should match the pathology, not the name."

Corticosteroid Injections: Short-Term Gain, Long-Term Concern

Corticosteroid injections are among the most frequently used interventions for tendinitis, but their risk-benefit profile requires careful consideration. They work by suppressing local inflammation and providing rapid pain relief.

A landmark randomized controlled trial published in The BMJ compared corticosteroid injection, physical therapy, and wait-and-see approaches for lateral epicondylitis in 165 patients [10]. At 6 weeks, corticosteroid injection produced the greatest pain reduction (mean difference of 15 points on a 100-point scale compared with physical therapy). By 26 weeks, the corticosteroid group showed significantly worse outcomes than both comparators, with a recurrence rate of 72% versus 8% for physical therapy.

These findings have been replicated across tendon sites. A systematic review and meta-analysis of 41 trials found that corticosteroid injections provided short-term benefit (4-8 weeks) but inferior long-term outcomes across rotator cuff, lateral epicondyle, and Achilles tendinopathies [11].

Repeated injections compound the risk. Corticosteroids reduce tenocyte viability, decrease collagen synthesis, and cause structural changes that weaken the tendon. The risk of Achilles tendon rupture increases significantly after multiple peritendinous injections. Most guidelines now recommend a maximum of three injections per site, spaced at least 6 weeks apart.

Specific considerations by tendon location:

• Rotator cuff: Subacromial injection is the most supported application, with moderate evidence for short-term pain relief
• Lateral epicondyle (tennis elbow): Strong evidence against repeated injection due to high recurrence rates
• Achilles tendon: Injection near or into the Achilles is generally avoided due to rupture risk. Ultrasound guidance is mandatory if injection is considered
• De Quervain tendinopathy: A single injection into the first dorsal compartment has relatively strong evidence, with cure rates of 62% to 83% after a single injection [12]

Emerging and Adjunctive Drug Therapies

Beyond standard NSAIDs and corticosteroids, several pharmacologic and biologic treatments are under investigation for tendinopathy.

Platelet-rich plasma (PRP). PRP injections deliver concentrated growth factors to the tendon in an effort to stimulate repair. Results remain inconsistent. A 2021 meta-analysis in the American Journal of Sports Medicine pooling 18 randomized trials found PRP provided modest benefit for chronic lateral epicondylitis but no clear advantage over placebo for Achilles or patellar tendinopathy [13]. PRP is not FDA-approved for tendinopathy, and insurance coverage varies.

Glyceryl trinitrate (GTN) patches. Topical nitroglycerin applied over the affected tendon delivers nitric oxide, which plays a role in collagen synthesis. A randomized trial of 86 patients with chronic Achilles tendinopathy found GTN patches combined with eccentric exercises produced greater improvement than exercise alone at 24 weeks [14]. The approach has not entered mainstream guidelines, and headache is a common side effect.

Collagen peptide supplementation. Oral collagen peptides (5-15 g daily) taken before exercise may support tendon repair by increasing collagen synthesis. A 2019 study in the American Journal of Clinical Nutrition showed that vitamin C-enriched gelatin supplementation increased collagen synthesis markers in tendon-like tissue [15]. Clinical outcomes data remain limited.

Sclerosing injections (polidocanol). These target neovascularization in chronic tendinopathy. Small trials show promise for Achilles and patellar tendinopathy, but evidence is insufficient for routine use.

None of these emerging therapies should replace the established foundation of eccentric exercise and load management for chronic tendinopathy.

Non-Drug Causes: Overuse, Biomechanics, and Systemic Conditions

Medications are only one piece of the tendinitis picture. Most cases originate from mechanical overuse, and a complete assessment must consider non-pharmacologic contributors.

Repetitive strain is the leading cause. Occupations requiring repetitive wrist extension (typing, assembly work), overhead arm movements (painting, construction), or running on hard surfaces without adequate recovery time create microtrauma that outpaces the tendon's repair capacity. The Occupational Safety and Health Administration (OSHA) estimates that musculoskeletal disorders including tendinopathy account for approximately 30% of all workplace injuries requiring time off [16].

Biomechanical factors including flat feet, leg-length discrepancy, and poor joint alignment concentrate stress on specific tendons. Sudden increases in training volume (the "too much, too soon" pattern) are a consistent trigger in athletes. A prospective study of 725 military recruits found the incidence of Achilles tendinopathy was 52% higher in those who increased running volume by more than 30% over a two-week period [17].

Systemic conditions raise baseline tendinopathy risk. Diabetes mellitus alters tendon collagen cross-linking through glycation, increasing stiffness and reducing tensile strength. Rheumatoid arthritis, psoriatic arthritis, and gout can directly inflame tendon sheaths. Hypothyroidism slows connective tissue turnover and is associated with bilateral tendinopathy, particularly of the shoulder.

Age is a non-modifiable risk factor. Tendon blood supply, water content, and proteoglycan concentration all decline after age 35 to 40. The cumulative effect reduces the tendon's ability to withstand load and recover from microinjury.

When to Seek Medical Evaluation

Most tendinitis resolves with rest, activity modification, and short-term NSAID use. Certain features warrant prompt medical attention.

See a clinician if you experience:

• Sudden, severe pain with a popping sensation (possible tendon rupture)
• Inability to move the affected joint through its normal range
• Symptoms lasting longer than 2 to 3 weeks despite conservative treatment
• Tendon pain that started after beginning a new medication, particularly a fluoroquinolone
• Night pain that disrupts sleep, suggesting more advanced tendon disease or an alternative diagnosis
• Redness, warmth, and fever over the tendon (possible infectious tenosynovitis, a surgical emergency)

Diagnosis typically involves clinical examination and may include ultrasound or MRI to evaluate tendon integrity. Ultrasound has a sensitivity of 79% and specificity of 94% for detecting Achilles tendon tears [18]. MRI provides superior soft-tissue detail and can identify partial tears, tendinosis changes, and surrounding bursitis.

If a drug-induced cause is suspected, the prescribing physician should evaluate whether the medication can be discontinued or substituted. For fluoroquinolone-associated tendinitis, the antibiotic should be stopped immediately and an alternative class used for the remaining course of infection.

Patients taking statins who develop tendon symptoms should discuss the risk-benefit ratio of continuing therapy with their cardiologist. Switching to a different statin or reducing the dose resolves symptoms in most cases. Complete statin discontinuation requires weighing tendon symptoms against cardiovascular risk reduction.